Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Terumo Preparing to Launch HeartSheet; Sees Room for Improvements in Production and Quality Control
April 7, 2016
- MSD, Alfresa, Aerosense to Collaborate in Developing a Drug Delivery Business Using Drones
April 7, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan
April 6, 2016
- Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
April 6, 2016
- JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
April 6, 2016
- Astellas Strikes New Research Pact with AIST for Chagas’ Disease
April 5, 2016
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
- Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
April 4, 2016
- Astellas Completes Transfer of Dermatology Biz to LEO Pharma
April 4, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
April 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
- Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
- Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
April 1, 2016
- Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
April 1, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…